Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Polyinosinic-polycytidylic acid (sodium)

Polyinosinic-polycytidylic acid (Poly (I:C) ) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I) -like receptors (RIG-I and MDA5) . Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis[1][2].

Product Specifications

CAS Number

[42424-50-0]

Product Name Alternative

Poly (I:C) (sodium)

UNSPSC

12352211

Target

Apoptosis; Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/polyinosinic-polycytidylic-acid-sodium.html

Purity

99.0

Solubility

H2O : 10 mg/mL (ultrasonic; warming)

Smiles

O[C@H]1[C@@H](O[C@H](COP(O)(O)=O)[C@H]1O)N2C3=C(C(NC=N3)=O)N=C2.O[C@H]4[C@H](N5C(N=C(N)C=C5)=O)O[C@H](COP(O)(O)=O)[C@H]4O.[x].[x].[Na].[x]

Molecular Formula

(C10H13N4O8P) x. (C9H14N3O8P) x.xNa

References & Citations

[1]Besch R, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest. 2009 Aug;119 (8) :2399-411.|[2]Cheng YS, et al. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther. 2010 Dec 15;10 (12) :1219-23.|[3]Robert Field, et al. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun. 2010 Aug;24 (6) :996-1007.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

TLR3

Citation 01

Adv Funct Mater. 29 August 2022.|Liver Int. 2022 Dec;42 (12) :2724-2742.|Mol Ther Oncolytics. 2022 Aug 25:26:413-428.|Phytomedicine. 2021 Apr:84:153495.|SSRN. 2021 Apr 26.|ACS Nano. 2025 Feb 4;19 (4) :4195-4212.|Acta Pharm Sin B. 2025 Jul 9.|Autophagy. 2024 May 18.|Biochem Biophys Res Commun. 2024 Apr 16:704:149661.|bioRxiv. 2024 Dec 8:2024.12.07.627371.|bioRxiv. 2024 September 23.|Cancer Immunol Res. 2024 Oct 1;12 (10) :1438-1451.|Cancer Med. 2023 Jul;12 (14) :15676-15690.|Cell Death Discov. 2025 Jul 25;11 (1) :345.|Cell Signal. 2025 Apr 15:132:111807.|Chem Biol Drug Des. 2023 Nov;102 (5) :1110-1120.|Chem Biol Drug Des. 2025 Nov;106 (5) :e70196.|Chem Eng J. 2021 Aug 15:418:129392.|Clin Cosmet Investig Dermatol. 2024 May 14:17:1093-1105.|Clin Transl Med. 2024 Sep;14 (9) :e70027.|Curr Issues Mol Biol. 2025 May 14;47 (5) :361.|Curr Microbiol. 2024 Aug 6;81 (9) :296.|Dev Comp Immunol. 2025 Dec:173:105527.|Dev Comp Immunol. 2025 Sep 29:172:105483.|FASEB J. 2024 Mar 31;38 (6) :e23551.|Food Front. 2025 Nov 6.|Hepatology. 2025 Nov 7.|Immunity. 2025 Aug 12:S1074-7613 (25) 00314-0.|Int Immunopharmacol. 2025 Jan 11:147:114033.|J Exp Clin Cancer Res. 2025 Feb 7;44 (1) :45.|J Extracell Vesicles. 2025 May;14 (5) :e70083.|J Innate Immun. 2025 Jul 28:1-27.|J Transl Med. 2025 Nov 10;23 (1) :1252.|J Virol. 2025 Aug 19;99 (8) :e0049825.|Mol Ther. 2025 Dec 3;33 (12) :6146-6159.|Nat Cell Biol. 2025 Apr;27 (4) :683-695.|Nat Commun. 2025 Feb 24;16 (1) :1909.|Nat Commun. 2025 Jun 3;16 (1) :5140.|Nature. 2025 Jul;643 (8072) :810-819.|Patent. US20250235423A1.|Res Sq. 2024 Nov 14.|SSRN. 2023 Apr 29.|Vet Res. 2024 Sep 27;55 (1) :115.|Vet Res. 2025 Nov 5;56 (1) :210.|Virol Sin. 2023 Jun;38 (3) :335-343.|Virol Sin. 2023 Oct;38 (5) :741-754.|World J Tradit Chin Med. 2025 Oct 28.|Vet Microbiol. 2025 May:304:110459.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Recombinant Human Orexin-A protein (TRX,His tag)
MBS2570725-01 0.02 mg

Recombinant Human Orexin-A protein (TRX,His tag)

Ask
View Details
Recombinant Human Orexin-A protein (TRX,His tag)
MBS2570725-02 0.1 mg

Recombinant Human Orexin-A protein (TRX,His tag)

Ask
View Details
Recombinant Human Orexin-A protein (TRX,His tag)
MBS2570725-03 5x 0.1 mg

Recombinant Human Orexin-A protein (TRX,His tag)

Ask
View Details
Recombinant Pseudomonas syringae pv. syringae Phosphoglycerate kinase (pgk)
MBS1446815-01 0.02 mg (E-Coli)

Recombinant Pseudomonas syringae pv. syringae Phosphoglycerate kinase (pgk)

Ask
View Details
Recombinant Pseudomonas syringae pv. syringae Phosphoglycerate kinase (pgk)
MBS1446815-02 0.02 mg (Yeast)

Recombinant Pseudomonas syringae pv. syringae Phosphoglycerate kinase (pgk)

Ask
View Details
Recombinant Pseudomonas syringae pv. syringae Phosphoglycerate kinase (pgk)
MBS1446815-03 0.1 mg (E-Coli)

Recombinant Pseudomonas syringae pv. syringae Phosphoglycerate kinase (pgk)

Ask
View Details